This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
il-13
Interleukin-13
IL-13 (IL13, chr5q31.1) signals via IL-13Rα1/IL-4Rα type II receptor → JAK1/TYK2 → STAT6; drives goblet cell metaplasia, airway hyperresponsiveness, skin barrier disruption, and fibrosis; tralokinumab and lebrikizumab (anti-IL-13 mAbs) are FDA-approved for atopic dermatitis.
Entry Metadata
| Field | Value |
|---|---|
| ID | il-13 |
| Name | Interleukin-13 |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-2261. · PubMed 9856949
- Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. · PubMed 33000465